Beam Therapeutics (BEAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Election of three Class III director nominees for three-year terms ending at the 2029 annual meeting.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting for all three director nominees: John Evans, John Maraganore, Ph.D., and Christi Shaw.
Directors to serve three-year terms if elected, expiring at the 2029 annual meeting.
Executive compensation and say-on-pay
Advisory vote to approve compensation of named executive officers is included as a voting item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beam Therapeutics
- BEAM-304 base editing platform shows promise for durable PKU correction and broad patient coverage.BEAM
Conference presentation - Strong cash, rising revenue, and major clinical milestones set up pivotal 2026 filings.BEAM
Q2 2026 - Base editing platform delivers strong clinical progress in sickle cell and liver disease programs.BEAM
H.C. Wainwright 27th Annual Global Investment Conference - All proposals passed, including director elections and auditor ratification, with no questions raised.BEAM
AGM 2026 - Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value.BEAM
RBC Capital Markets Global Healthcare Conference 2026 - Revenue and clinical milestones surged, net loss narrowed, and cash runway extends to mid-2029.BEAM
Q1 2026 - Director elections, auditor ratification, and executive pay are up for shareholder approval.BEAM
Proxy filing - Single-dose BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD.BEAM
Study result - Expanded PKU pipeline, secured $500M financing, and posted strong Q4 net income for 2025.BEAM
Q4 2025